Literature DB >> 27807004

Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival.

Catherine Ling1, Celso Pouget1, Fabien Rech1, Robin Pflaum1, Mathilde Treffel1, Franck Bielle1, Karima Mokhtari1, Jean-Matthieu Casse1, Jean-Michel Vignaud1, Michel Kalamarides1, Matthieu Peyre1, Guillaume Gauchotte1.   

Abstract

Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p = 0.0004, and p = 0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p = 0.017, p = 0.021, and p = 0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p = 0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.
© 2016 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  CD105; CD34; Endothelial cell hypertrophy; Meningioma; Microvascular proliferation; Microvessel density; Vascularization.

Mesh:

Year:  2016        PMID: 27807004     DOI: 10.1093/jnen/nlw095

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  6 in total

1.  The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.

Authors:  Elmar Kirches; Tabea Steffen; Natalie Waldt; Eva Hebert; Doreen Pachow; Annette Wilisch-Neumann; Gerburg Keilhoff; Thomas Schneider; Werner E K Braunsdorf; Jan-Peter Warnke; Christian Mawrin
Journal:  J Neurooncol       Date:  2018-02-21       Impact factor: 4.130

2.  Lentiviral-Induced Spinal Cord Gliomas in Rat Model.

Authors:  Purva P Nagarajan; Muhibullah S Tora; Stewart G Neill; Thais Federici; Pavlos Texakalidis; Anthony Donsante; Peter Canoll; Kecheng Lei; Nicholas M Boulis
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

3.  Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.

Authors:  María Del Mar Álvarez-Torres; Elies Fuster-García; Javier Juan-Albarracín; Gaspar Reynés; Fernando Aparici-Robles; Jaime Ferrer-Lozano; Juan Miguel García-Gómez
Journal:  BMC Cancer       Date:  2022-01-06       Impact factor: 4.430

4.  A vascularized tumoroid model for human glioblastoma angiogenesis.

Authors:  Agavi Stavropoulou Tatla; Alexander W Justin; Colin Watts; Athina E Markaki
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

5.  Preclinical anti-angiogenic and anti-cancer activities of BAY1143269 in glioblastoma via targeting oncogenic protein expression.

Authors:  Weifeng Wan; Xin Zhang; Changren Huang; Ligang Chen; Xiaobo Yang; Kunyang Bao; Tangming Peng
Journal:  Pharmacol Res Perspect       Date:  2022-08

6.  Evaluation of AQP4/TRPV4 Channel Co-expression, Microvessel Density, and its Association with Peritumoral Brain Edema in Intracranial Meningiomas.

Authors:  Konstantinos Faropoulos; Afroditi Polia; Chrisi Tsakona; Eleanna Pitaraki; Athanasia Moutafidi; George Gatzounis; Martha Assimakopoulou
Journal:  J Mol Neurosci       Date:  2021-02-04       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.